keyword
MENU ▼
Read by QxMD icon Read
search

Alan K. Burnett

keyword
https://www.readbyqxmd.com/read/27872058/a-randomised-assessment-of-adding-the-kinase-inhibitor-lestaurtinib-to-1st-line-chemotherapy-for-flt3-mutated-aml
#1
Steven Knapper, Nigel Russell, Amanda Gilkes, Robert K Hills, Rosemary E Gale, James D Cavenagh, Gail Jones, Lars Kjeldsen, Michael R Grunwald, Ian Thomas, Heiko Konig, Mark J Levis, Alan K Burnett
The clinical benefit of adding FLT3-directed small molecule therapy to standard first-line treatment of acute myeloid leukemia (AML) has not yet been established. As part of the UK AML15 and 17 trials, patients with previously-untreated AML and confirmed FLT3-activating mutations, mostly aged <60 years, were randomised to receive oral Lestaurtinib (CEP701), or not, following each of four cycles of induction and consolidation chemotherapy. Lestaurtinib was commenced 2 days after completing chemotherapy and administered in cycles of up to 28 days...
November 21, 2016: Blood
https://www.readbyqxmd.com/read/27669008/normal-hematopoietic-progenitor-subsets-have-distinct-reactive-oxygen-species-bcl2-and-cell-cycle-profiles-that-are-decoupled-from-maturation-in-acute-myeloid-leukemia
#2
Naeem Khan, Robert K Hills, Steve Knapper, Lora Steadman, Ushna Qureshi, Jerrald L Rector, Charlotte Bradbury, Nigel H Russell, Paresh Vyas, Alan K Burnett, David Grimwade, Paul S Hole, Sylvie D Freeman
In acute myeloid leukemia (AML) quiescence and low oxidative state, linked to BCL2 mitochondrial regulation, endow leukemic stem cells (LSC) with treatment-resistance. LSC in CD34+ and more mature CD34- AML have heterogeneous immunophenotypes overlapping with normal stem/progenitor cells (SPC) but may be differentiated by functional markers. We therefore investigated the oxidative/reactive oxygen species (ROS) profile, its relationship with cell-cycle/BCL2 for normal SPC, and whether altered in AML and myelodysplasia (MDS)...
2016: PloS One
https://www.readbyqxmd.com/read/26875020/autoimmune-diseases-and-myelodysplastic-syndromes
#3
COMPARATIVE STUDY
Rami S Komrokji, Austin Kulasekararaj, Najla H Al Ali, Shahram Kordasti, Emily Bart-Smith, Benjamin M Craig, Eric Padron, Ling Zhang, Jeffrey E Lancet, Javier Pinilla-Ibarz, Alan F List, Ghulam J Mufti, Pearlie K Epling-Burnette
Immune dysregulation and altered T-cell hemostasis play important roles in the pathogenesis of myelodysplastic syndromes (MDS). Recent studies suggest an increased risk of MDS among patients with autoimmune diseases. Here, we investigated the prevalence of autoimmune diseases among MDS patients, comparing characteristics and outcomes in those with and without autoimmune diseases. From our study group of 1408 MDS patients, 391 (28%) had autoimmune disease, with hypothyroidism being the most common type, accounting for 44% (n = 171) of patients (12% among all MDS patients analyzed)...
May 2016: American Journal of Hematology
https://www.readbyqxmd.com/read/26847745/the-value-of-molecular-stratification-for-cebpa-dm-and-npm1-mut-flt3-wt-genotypes-in-older-patients-with-acute-myeloid-leukaemia
#4
Glenda J Dickson, Sophia Bustraan, Robert K Hills, Akbar Ali, Anthony H Goldstone, Alan K Burnett, David C Linch, Rosemary E Gale
Older adult patients (≥60 years) with acute myeloid leukaemia (AML) are generally considered to be poor-risk and there is limited information available regarding risk stratification based on molecular characterization in this age group, particularly for the double-mutant CEBPA (CEBPA(DM) ) genotype. To investigate whether a molecular favourable-risk genotype can be identified, we investigated CEBPA, NPM1 and FLT3 status and prognostic impact in a cohort of 301 patients aged 60 years or more with intermediate-risk cytogenetics, all treated intensively...
February 2016: British Journal of Haematology
https://www.readbyqxmd.com/read/26821169/altered-posterior-cingulate-brain-metabolites-and-cognitive-dysfunction-in-preterm-adolescents
#5
Jeanie L Y Cheong, Alan Bainbridge, Peter J Anderson, Katherine J Lee, Alice C Burnett, Deanne K Thompson, Gehan Roberts, Stephen J Wood, Lex W Doyle, Nicola J Robertson
BACKGROUND: Extremely preterm (EP, <28 wk gestation) individuals have increased the risk of cognitive deficits compared with controls. The posterior cingulate region has an important role in cognitive function, but how this is affected by preterm birth is unknown. We aimed to compare brain metabolite ratios of neurons and cell membranes between EP 18-y olds and controls, and explore the association between metabolite ratios and cognitive outcomes. METHOD: A regional cohort of 150 EP and 134 controls were recruited for the study...
May 2016: Pediatric Research
https://www.readbyqxmd.com/read/26789727/assessment-of-minimal-residual-disease-in-standard-risk-aml
#6
RANDOMIZED CONTROLLED TRIAL
Adam Ivey, Robert K Hills, Michael A Simpson, Jelena V Jovanovic, Amanda Gilkes, Angela Grech, Yashma Patel, Neesa Bhudia, Hassan Farah, Joanne Mason, Kerry Wall, Susanna Akiki, Michael Griffiths, Ellen Solomon, Frank McCaughan, David C Linch, Rosemary E Gale, Paresh Vyas, Sylvie D Freeman, Nigel Russell, Alan K Burnett, David Grimwade
BACKGROUND: Despite the molecular heterogeneity of standard-risk acute myeloid leukemia (AML), treatment decisions are based on a limited number of molecular genetic markers and morphology-based assessment of remission. Sensitive detection of a leukemia-specific marker (e.g., a mutation in the gene encoding nucleophosmin [NPM1]) could improve prognostication by identifying submicroscopic disease during remission. METHODS: We used a reverse-transcriptase quantitative polymerase-chain-reaction assay to detect minimal residual disease in 2569 samples obtained from 346 patients with NPM1-mutated AML who had undergone intensive treatment in the National Cancer Research Institute AML17 trial...
February 4, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/26637397/cord-blood-derived-quiescent-cd34-cells-are-more-transcriptionally-matched-to-aml-blasts-than-cytokine-induced-normal-human-hematopoietic-cd34-cells
#7
Chinmay Munje, Robert K Hills, Anthony Whetton, Alan K Burnett, Richard L Darley, Alex Tonks
Acute myeloid leukemia (AML) is characterized by developmental arrest, which is thought to arise from transcriptional dysregulation of myeloid development programs. Hematopoietic stem and progenitor cells (HSPCs) isolated from human blood are frequently used as a normal comparator in AML studies. Previous studies have reported changes in the transcriptional program of genes involved in proliferation, differentiation, apoptosis, and homing when HSPCs were expanded ex vivo. The intrinsic functional differences between quiescent and dividing CD34+ HSPCs prompted us to determine whether fresh or cytokine-induced cord blood-derived CD34+ HSPCs are a more appropriate normal control compared to AML blasts...
2015: Gene Expression
https://www.readbyqxmd.com/read/26536169/comprehensive-molecular-characterization-of-papillary-renal-cell-carcinoma
#8
W Marston Linehan, Paul T Spellman, Christopher J Ricketts, Chad J Creighton, Suzanne S Fei, Caleb Davis, David A Wheeler, Bradley A Murray, Laura Schmidt, Cathy D Vocke, Myron Peto, Abu Amar M Al Mamun, Eve Shinbrot, Anurag Sethi, Samira Brooks, W Kimryn Rathmell, Angela N Brooks, Katherine A Hoadley, A Gordon Robertson, Denise Brooks, Reanne Bowlby, Sara Sadeghi, Hui Shen, Daniel J Weisenberger, Moiz Bootwalla, Stephen B Baylin, Peter W Laird, Andrew D Cherniack, Gordon Saksena, Scott Haake, Jun Li, Han Liang, Yiling Lu, Gordon B Mills, Rehan Akbani, Mark D M Leiserson, Benjamin J Raphael, Pavana Anur, Donald Bottaro, Laurence Albiges, Nandita Barnabas, Toni K Choueiri, Bogdan Czerniak, Andrew K Godwin, A Ari Hakimi, Thai H Ho, James Hsieh, Michael Ittmann, William Y Kim, Bhavani Krishnan, Maria J Merino, Kenna R Mills Shaw, Victor E Reuter, Ed Reznik, Carl S Shelley, Brian Shuch, Sabina Signoretti, Ramaprasad Srinivasan, Pheroze Tamboli, George Thomas, Satish Tickoo, Kenneth Burnett, Daniel Crain, Johanna Gardner, Kevin Lau, David Mallery, Scott Morris, Joseph D Paulauskis, Robert J Penny, Candace Shelton, W Troy Shelton, Mark Sherman, Eric Thompson, Peggy Yena, Melissa T Avedon, Jay Bowen, Julie M Gastier-Foster, Mark Gerken, Kristen M Leraas, Tara M Lichtenberg, Nilsa C Ramirez, Tracie Santos, Lisa Wise, Erik Zmuda, John A Demchok, Ina Felau, Carolyn M Hutter, Margi Sheth, Heidi J Sofia, Roy Tarnuzzer, Zhining Wang, Liming Yang, Jean C Zenklusen, Jiashan Zhang, Brenda Ayala, Julien Baboud, Sudha Chudamani, Jia Liu, Laxmi Lolla, Rashi Naresh, Todd Pihl, Qiang Sun, Yunhu Wan, Ye Wu, Adrian Ally, Miruna Balasundaram, Saianand Balu, Rameen Beroukhim, Tom Bodenheimer, Christian Buhay, Yaron S N Butterfield, Rebecca Carlsen, Scott L Carter, Hsu Chao, Eric Chuah, Amanda Clarke, Kyle R Covington, Mahmoud Dahdouli, Ninad Dewal, Noreen Dhalla, Harsha V Doddapaneni, Jennifer A Drummond, Stacey B Gabriel, Richard A Gibbs, Ranabir Guin, Walker Hale, Alicia Hawes, D Neil Hayes, Robert A Holt, Alan P Hoyle, Stuart R Jefferys, Steven J M Jones, Corbin D Jones, Divya Kalra, Christie Kovar, Lora Lewis, Jie Li, Yussanne Ma, Marco A Marra, Michael Mayo, Shaowu Meng, Matthew Meyerson, Piotr A Mieczkowski, Richard A Moore, Donna Morton, Lisle E Mose, Andrew J Mungall, Donna Muzny, Joel S Parker, Charles M Perou, Jeffrey Roach, Jacqueline E Schein, Steven E Schumacher, Yan Shi, Janae V Simons, Payal Sipahimalani, Tara Skelly, Matthew G Soloway, Carrie Sougnez, Angela Tam, Donghui Tan, Nina Thiessen, Umadevi Veluvolu, Min Wang, Matthew D Wilkerson, Tina Wong, Junyuan Wu, Liu Xi, Jane Zhou, Jason Bedford, Fengju Chen, Yao Fu, Mark Gerstein, David Haussler, Katayoon Kasaian, Phillip Lai, Shiyun Ling, Amie Radenbaugh, David Van Den Berg, John N Weinstein, Jingchun Zhu, Monique Albert, Iakovina Alexopoulou, Jeremiah J Andersen, J Todd Auman, John Bartlett, Sheldon Bastacky, Julie Bergsten, Michael L Blute, Lori Boice, Roni J Bollag, Jeff Boyd, Erik Castle, Ying-Bei Chen, John C Cheville, Erin Curley, Benjamin Davies, April DeVolk, Rajiv Dhir, Laura Dike, John Eckman, Jay Engel, Jodi Harr, Ronald Hrebinko, Mei Huang, Lori Huelsenbeck-Dill, Mary Iacocca, Bruce Jacobs, Michael Lobis, Jodi K Maranchie, Scott McMeekin, Jerome Myers, Joel Nelson, Jeremy Parfitt, Anil Parwani, Nicholas Petrelli, Brenda Rabeno, Somak Roy, Andrew L Salner, Joel Slaton, Melissa Stanton, R Houston Thompson, Leigh Thorne, Kelinda Tucker, Paul M Weinberger, Cynthia Winemiller, Leigh Anne Zach, Rosemary Zuna
BACKGROUND: Papillary renal-cell carcinoma, which accounts for 15 to 20% of renal-cell carcinomas, is a heterogeneous disease that consists of various types of renal cancer, including tumors with indolent, multifocal presentation and solitary tumors with an aggressive, highly lethal phenotype. Little is known about the genetic basis of sporadic papillary renal-cell carcinoma, and no effective forms of therapy for advanced disease exist. METHODS: We performed comprehensive molecular characterization of 161 primary papillary renal-cell carcinomas, using whole-exome sequencing, copy-number analysis, messenger RNA and microRNA sequencing, DNA-methylation analysis, and proteomic analysis...
January 14, 2016: New England Journal of Medicine
https://www.readbyqxmd.com/read/26416416/tp53-and-mdm2-single-nucleotide-polymorphisms-influence-survival-in-non-del-5q-myelodysplastic-syndromes
#9
Kathy L McGraw, Thomas Cluzeau, David A Sallman, Ashley A Basiorka, Brittany A Irvine, Ling Zhang, P K Epling-Burnette, Dana E Rollison, Mar Mallo, Lubomir Sokol, Francesc Solé, Jaroslaw Maciejewski, Alan F List
P53 is a key regulator of many cellular processes and is negatively regulated by the human homolog of murine double minute-2 (MDM2) E3 ubiquitin ligase. Single nucleotide polymorphisms (SNPs) of either gene alone, and in combination, are linked to cancer susceptibility, disease progression, and therapy response. We analyzed the interaction of TP53 R72P and MDM2 SNP309 SNPs in relationship to outcome in patients with myelodysplastic syndromes (MDS). Sanger sequencing was performed on DNA isolated from 208 MDS cases...
October 27, 2015: Oncotarget
https://www.readbyqxmd.com/read/26384238/arsenic-trioxide-and-all-trans-retinoic-acid-treatment-for-acute-promyelocytic-leukaemia-in-all-risk-groups-aml17-results-of-a-randomised-controlled-phase-3-trial
#10
RANDOMIZED CONTROLLED TRIAL
Alan K Burnett, Nigel H Russell, Robert K Hills, David Bowen, Jonathan Kell, Steve Knapper, Yvonne G Morgan, Jennie Lok, Angela Grech, Gail Jones, Asim Khwaja, Lone Friis, Mary Frances McMullin, Ann Hunter, Richard E Clark, David Grimwade
BACKGROUND: Acute promyelocytic leukaemia is a chemotherapy-sensitive subgroup of acute myeloid leukaemia characterised by the presence of the PML-RARA fusion transcript. The present standard of care, chemotherapy and all-trans retinoic acid (ATRA), results in a high proportion of patients being cured. In this study, we compare a chemotherapy-free ATRA and arsenic trioxide treatment regimen with the standard chemotherapy-based regimen (ATRA and idarubicin) in both high-risk and low-risk patients with acute promyelocytic leukaemia...
October 2015: Lancet Oncology
https://www.readbyqxmd.com/read/26364544/global-regional-and-national-comparative-risk-assessment-of-79-behavioural-environmental-and-occupational-and-metabolic-risks-or-clusters-of-risks-in-188-countries-1990-2013-a-systematic-analysis-for-the-global-burden-of-disease-study-2013
#11
COMPARATIVE STUDY
Mohammad H Forouzanfar, Lily Alexander, H Ross Anderson, Victoria F Bachman, Stan Biryukov, Michael Brauer, Richard Burnett, Daniel Casey, Matthew M Coates, Aaron Cohen, Kristen Delwiche, Kara Estep, Joseph J Frostad, K C Astha, Hmwe H Kyu, Maziar Moradi-Lakeh, Marie Ng, Erica Leigh Slepak, Bernadette A Thomas, Joseph Wagner, Gunn Marit Aasvang, Cristiana Abbafati, Ayse Abbasoglu Ozgoren, Foad Abd-Allah, Semaw F Abera, Victor Aboyans, Biju Abraham, Jerry Puthenpurakal Abraham, Ibrahim Abubakar, Niveen M E Abu-Rmeileh, Tania C Aburto, Tom Achoki, Ademola Adelekan, Koranteng Adofo, Arsène K Adou, José C Adsuar, Ashkan Afshin, Emilie E Agardh, Mazin J Al Khabouri, Faris H Al Lami, Sayed Saidul Alam, Deena Alasfoor, Mohammed I Albittar, Miguel A Alegretti, Alicia V Aleman, Zewdie A Alemu, Rafael Alfonso-Cristancho, Samia Alhabib, Raghib Ali, Mohammed K Ali, François Alla, Peter Allebeck, Peter J Allen, Ubai Alsharif, Elena Alvarez, Nelson Alvis-Guzman, Adansi A Amankwaa, Azmeraw T Amare, Emmanuel A Ameh, Omid Ameli, Heresh Amini, Walid Ammar, Benjamin O Anderson, Carl Abelardo T Antonio, Palwasha Anwari, Solveig Argeseanu Cunningham, Johan Arnlöv, Valentina S Arsic Arsenijevic, Al Artaman, Rana J Asghar, Reza Assadi, Lydia S Atkins, Charles Atkinson, Marco A Avila, Baffour Awuah, Alaa Badawi, Maria C Bahit, Talal Bakfalouni, Kalpana Balakrishnan, Shivanthi Balalla, Ravi Kumar Balu, Amitava Banerjee, Ryan M Barber, Suzanne L Barker-Collo, Simon Barquera, Lars Barregard, Lope H Barrero, Tonatiuh Barrientos-Gutierrez, Ana C Basto-Abreu, Arindam Basu, Sanjay Basu, Mohammed O Basulaiman, Carolina Batis Ruvalcaba, Justin Beardsley, Neeraj Bedi, Tolesa Bekele, Michelle L Bell, Corina Benjet, Derrick A Bennett, Habib Benzian, Eduardo Bernabé, Tariku J Beyene, Neeraj Bhala, Ashish Bhalla, Zulfiqar A Bhutta, Boris Bikbov, Aref A Bin Abdulhak, Jed D Blore, Fiona M Blyth, Megan A Bohensky, Berrak Bora Başara, Guilherme Borges, Natan M Bornstein, Dipan Bose, Soufiane Boufous, Rupert R Bourne, Michael Brainin, Alexandra Brazinova, Nicholas J Breitborde, Hermann Brenner, Adam D M Briggs, David M Broday, Peter M Brooks, Nigel G Bruce, Traolach S Brugha, Bert Brunekreef, Rachelle Buchbinder, Linh N Bui, Gene Bukhman, Andrew G Bulloch, Michael Burch, Peter G J Burney, Ismael R Campos-Nonato, Julio C Campuzano, Alejandra J Cantoral, Jack Caravanos, Rosario Cárdenas, Elisabeth Cardis, David O Carpenter, Valeria Caso, Carlos A Castañeda-Orjuela, Ruben E Castro, Ferrán Catalá-López, Fiorella Cavalleri, Alanur Çavlin, Vineet K Chadha, Jung-Chen Chang, Fiona J Charlson, Honglei Chen, Wanqing Chen, Zhengming Chen, Peggy P Chiang, Odgerel Chimed-Ochir, Rajiv Chowdhury, Costas A Christophi, Ting-Wu Chuang, Sumeet S Chugh, Massimo Cirillo, Thomas K D Claßen, Valentina Colistro, Mercedes Colomar, Samantha M Colquhoun, Alejandra G Contreras, Cyrus Cooper, Kimberly Cooperrider, Leslie T Cooper, Josef Coresh, Karen J Courville, Michael H Criqui, Lucia Cuevas-Nasu, James Damsere-Derry, Hadi Danawi, Lalit Dandona, Rakhi Dandona, Paul I Dargan, Adrian Davis, Dragos V Davitoiu, Anand Dayama, E Filipa de Castro, Vanessa De la Cruz-Góngora, Diego De Leo, Graça de Lima, Louisa Degenhardt, Borja del Pozo-Cruz, Robert P Dellavalle, Kebede Deribe, Sarah Derrett, Don C Des Jarlais, Muluken Dessalegn, Gabrielle A deVeber, Karen M Devries, Samath D Dharmaratne, Mukesh K Dherani, Daniel Dicker, Eric L Ding, Klara Dokova, E Ray Dorsey, Tim R Driscoll, Leilei Duan, Adnan M Durrani, Beth E Ebel, Richard G Ellenbogen, Yousef M Elshrek, Matthias Endres, Sergey P Ermakov, Holly E Erskine, Babak Eshrati, Alireza Esteghamati, Saman Fahimi, Emerito Jose A Faraon, Farshad Farzadfar, Derek F J Fay, Valery L Feigin, Andrea B Feigl, Seyed-Mohammad Fereshtehnejad, Alize J Ferrari, Cleusa P Ferri, Abraham D Flaxman, Thomas D Fleming, Nataliya Foigt, Kyle J Foreman, Urbano Fra Paleo, Richard C Franklin, Belinda Gabbe, Lynne Gaffikin, Emmanuela Gakidou, Amiran Gamkrelidze, Fortuné G Gankpé, Ron T Gansevoort, Francisco A García-Guerra, Evariste Gasana, Johanna M Geleijnse, Bradford D Gessner, Pete Gething, Katherine B Gibney, Richard F Gillum, Ibrahim A M Ginawi, Maurice Giroud, Giorgia Giussani, Shifalika Goenka, Ketevan Goginashvili, Hector Gomez Dantes, Philimon Gona, Teresita Gonzalez de Cosio, Dinorah González-Castell, Carolyn C Gotay, Atsushi Goto, Hebe N Gouda, Richard L Guerrant, Harish C Gugnani, Francis Guillemin, David Gunnell, Rahul Gupta, Rajeev Gupta, Reyna A Gutiérrez, Nima Hafezi-Nejad, Holly Hagan, Maria Hagstromer, Yara A Halasa, Randah R Hamadeh, Mouhanad Hammami, Graeme J Hankey, Yuantao Hao, Hilda L Harb, Tilahun Nigatu Haregu, Josep Maria Haro, Rasmus Havmoeller, Simon I Hay, Mohammad T Hedayati, Ileana B Heredia-Pi, Lucia Hernandez, Kyle R Heuton, Pouria Heydarpour, Martha Hijar, Hans W Hoek, Howard J Hoffman, John C Hornberger, H Dean Hosgood, Damian G Hoy, Mohamed Hsairi, Guoqing Hu, Howard Hu, Cheng Huang, John J Huang, Bryan J Hubbell, Laetitia Huiart, Abdullatif Husseini, Marissa L Iannarone, Kim M Iburg, Bulat T Idrisov, Nayu Ikeda, Kaire Innos, Manami Inoue, Farhad Islami, Samaya Ismayilova, Kathryn H Jacobsen, Henrica A Jansen, Deborah L Jarvis, Simerjot K Jassal, Alejandra Jauregui, Sudha Jayaraman, Panniyammakal Jeemon, Paul N Jensen, Vivekanand Jha, Fan Jiang, Guohong Jiang, Ying Jiang, Jost B Jonas, Knud Juel, Haidong Kan, Sidibe S Kany Roseline, Nadim E Karam, André Karch, Corine K Karema, Ganesan Karthikeyan, Anil Kaul, Norito Kawakami, Dhruv S Kazi, Andrew H Kemp, Andre P Kengne, Andre Keren, Yousef S Khader, Shams Eldin Ali Hassan Khalifa, Ejaz A Khan, Young-Ho Khang, Shahab Khatibzadeh, Irma Khonelidze, Christian Kieling, Daniel Kim, Sungroul Kim, Yunjin Kim, Ruth W Kimokoti, Yohannes Kinfu, Jonas M Kinge, Brett M Kissela, Miia Kivipelto, Luke D Knibbs, Ann Kristin Knudsen, Yoshihiro Kokubo, M Rifat Kose, Soewarta Kosen, Alexander Kraemer, Michael Kravchenko, Sanjay Krishnaswami, Hans Kromhout, Tiffany Ku, Barthelemy Kuate Defo, Burcu Kucuk Bicer, Ernst J Kuipers, Chanda Kulkarni, Veena S Kulkarni, G Anil Kumar, Gene F Kwan, Taavi Lai, Arjun Lakshmana Balaji, Ratilal Lalloo, Tea Lallukka, Hilton Lam, Qing Lan, Van C Lansingh, Heidi J Larson, Anders Larsson, Dennis O Laryea, Pablo M Lavados, Alicia E Lawrynowicz, Janet L Leasher, Jong-Tae Lee, James Leigh, Ricky Leung, Miriam Levi, Yichong Li, Yongmei Li, Juan Liang, Xiaofeng Liang, Stephen S Lim, M Patrice Lindsay, Steven E Lipshultz, Shiwei Liu, Yang Liu, Belinda K Lloyd, Giancarlo Logroscino, Stephanie J London, Nancy Lopez, Joannie Lortet-Tieulent, Paulo A Lotufo, Rafael Lozano, Raimundas Lunevicius, Jixiang Ma, Stefan Ma, Vasco M P Machado, Michael F MacIntyre, Carlos Magis-Rodriguez, Abbas A Mahdi, Marek Majdan, Reza Malekzadeh, Srikanth Mangalam, Christopher C Mapoma, Marape Marape, Wagner Marcenes, David J Margolis, Christopher Margono, Guy B Marks, Randall V Martin, Melvin B Marzan, Mohammad T Mashal, Felix Masiye, Amanda J Mason-Jones, Kunihiro Matsushita, Richard Matzopoulos, Bongani M Mayosi, Tasara T Mazorodze, Abigail C McKay, Martin McKee, Abigail McLain, Peter A Meaney, Catalina Medina, Man Mohan Mehndiratta, Fabiola Mejia-Rodriguez, Wubegzier Mekonnen, Yohannes A Melaku, Michele Meltzer, Ziad A Memish, Walter Mendoza, George A Mensah, Atte Meretoja, Francis Apolinary Mhimbira, Renata Micha, Ted R Miller, Edward J Mills, Awoke Misganaw, Santosh Mishra, Norlinah Mohamed Ibrahim, Karzan A Mohammad, Ali H Mokdad, Glen L Mola, Lorenzo Monasta, Julio C Montañez Hernandez, Marcella Montico, Ami R Moore, Lidia Morawska, Rintaro Mori, Joanna Moschandreas, Wilkister N Moturi, Dariush Mozaffarian, Ulrich O Mueller, Mitsuru Mukaigawara, Erin C Mullany, Kinnari S Murthy, Mohsen Naghavi, Ziad Nahas, Aliya Naheed, Kovin S Naidoo, Luigi Naldi, Devina Nand, Vinay Nangia, K M Venkat Narayan, Denis Nash, Bruce Neal, Chakib Nejjari, Sudan P Neupane, Charles R Newton, Frida N Ngalesoni, Jean de Dieu Ngirabega, Grant Nguyen, Nhung T Nguyen, Mark J Nieuwenhuijsen, Muhammad I Nisar, José R Nogueira, Joan M Nolla, Sandra Nolte, Ole F Norheim, Rosana E Norman, Bo Norrving, Luke Nyakarahuka, In-Hwan Oh, Takayoshi Ohkubo, Bolajoko O Olusanya, Saad B Omer, John Nelson Opio, Ricardo Orozco, Rodolfo S Pagcatipunan, Amanda W Pain, Jeyaraj D Pandian, Carlo Irwin A Panelo, Christina Papachristou, Eun-Kee Park, Charles D Parry, Angel J Paternina Caicedo, Scott B Patten, Vinod K Paul, Boris I Pavlin, Neil Pearce, Lilia S Pedraza, Andrea Pedroza, Ljiljana Pejin Stokic, Ayfer Pekericli, David M Pereira, Rogelio Perez-Padilla, Fernando Perez-Ruiz, Norberto Perico, Samuel A L Perry, Aslam Pervaiz, Konrad Pesudovs, Carrie B Peterson, Max Petzold, Michael R Phillips, Hwee Pin Phua, Dietrich Plass, Dan Poenaru, Guilherme V Polanczyk, Suzanne Polinder, Constance D Pond, C Arden Pope, Daniel Pope, Svetlana Popova, Farshad Pourmalek, John Powles, Dorairaj Prabhakaran, Noela M Prasad, Dima M Qato, Amado D Quezada, D Alex A Quistberg, Lionel Racapé, Anwar Rafay, Kazem Rahimi, Vafa Rahimi-Movaghar, Sajjad Ur Rahman, Murugesan Raju, Ivo Rakovac, Saleem M Rana, Mayuree Rao, Homie Razavi, K Srinath Reddy, Amany H Refaat, Jürgen Rehm, Giuseppe Remuzzi, Antonio L Ribeiro, Patricia M Riccio, Lee Richardson, Anne Riederer, Margaret Robinson, Anna Roca, Alina Rodriguez, David Rojas-Rueda, Isabelle Romieu, Luca Ronfani, Robin Room, Nobhojit Roy, George M Ruhago, Lesley Rushton, Nsanzimana Sabin, Ralph L Sacco, Sukanta Saha, Ramesh Sahathevan, Mohammad Ali Sahraian, Joshua A Salomon, Deborah Salvo, Uchechukwu K Sampson, Juan R Sanabria, Luz Maria Sanchez, Tania G Sánchez-Pimienta, Lidia Sanchez-Riera, Logan Sandar, Itamar S Santos, Amir Sapkota, Maheswar Satpathy, James E Saunders, Monika Sawhney, Mete I Saylan, Peter Scarborough, Jürgen C Schmidt, Ione J C Schneider, Ben Schöttker, David C Schwebel, James G Scott, Soraya Seedat, Sadaf G Sepanlou, Berrin Serdar, Edson E Servan-Mori, Gavin Shaddick, Saeid Shahraz, Teresa Shamah Levy, Siyi Shangguan, Jun She, Sara Sheikhbahaei, Kenji Shibuya, Hwashin H Shin, Yukito Shinohara, Rahman Shiri, Kawkab Shishani, Ivy Shiue, Inga D Sigfusdottir, Donald H Silberberg, Edgar P Simard, Shireen Sindi, Abhishek Singh, Gitanjali M Singh, Jasvinder A Singh, Vegard Skirbekk, Karen Sliwa, Michael Soljak, Samir Soneji, Kjetil Søreide, Sergey Soshnikov, Luciano A Sposato, Chandrashekhar T Sreeramareddy, Nicolas J C Stapelberg, Vasiliki Stathopoulou, Nadine Steckling, Dan J Stein, Murray B Stein, Natalie Stephens, Heidi Stöckl, Kurt Straif, Konstantinos Stroumpoulis, Lela Sturua, Bruno F Sunguya, Soumya Swaminathan, Mamta Swaroop, Bryan L Sykes, Karen M Tabb, Ken Takahashi, Roberto T Talongwa, Nikhil Tandon, David Tanne, Marcel Tanner, Mohammad Tavakkoli, Braden J Te Ao, Carolina M Teixeira, Martha M Téllez Rojo, Abdullah S Terkawi, José Luis Texcalac-Sangrador, Sarah V Thackway, Blake Thomson, Andrew L Thorne-Lyman, Amanda G Thrift, George D Thurston, Taavi Tillmann, Myriam Tobollik, Marcello Tonelli, Fotis Topouzis, Jeffrey A Towbin, Hideaki Toyoshima, Jefferson Traebert, Bach X Tran, Leonardo Trasande, Matias Trillini, Ulises Trujillo, Zacharie Tsala Dimbuene, Miltiadis Tsilimbaris, Emin Murat Tuzcu, Uche S Uchendu, Kingsley N Ukwaja, Selen B Uzun, Steven van de Vijver, Rita Van Dingenen, Coen H van Gool, Jim van Os, Yuri Y Varakin, Tommi J Vasankari, Ana Maria N Vasconcelos, Monica S Vavilala, Lennert J Veerman, Gustavo Velasquez-Melendez, N Venketasubramanian, Lakshmi Vijayakumar, Salvador Villalpando, Francesco S Violante, Vasiliy Victorovich Vlassov, Stein Emil Vollset, Gregory R Wagner, Stephen G Waller, Mitchell T Wallin, Xia Wan, Haidong Wang, JianLi Wang, Linhong Wang, Wenzhi Wang, Yanping Wang, Tati S Warouw, Charlotte H Watts, Scott Weichenthal, Elisabete Weiderpass, Robert G Weintraub, Andrea Werdecker, K Ryan Wessells, Ronny Westerman, Harvey A Whiteford, James D Wilkinson, Hywel C Williams, Thomas N Williams, Solomon M Woldeyohannes, Charles D A Wolfe, John Q Wong, Anthony D Woolf, Jonathan L Wright, Brittany Wurtz, Gelin Xu, Lijing L Yan, Gonghuan Yang, Yuichiro Yano, Pengpeng Ye, Muluken Yenesew, Gökalp K Yentür, Paul Yip, Naohiro Yonemoto, Seok-Jun Yoon, Mustafa Z Younis, Zourkaleini Younoussi, Chuanhua Yu, Maysaa E Zaki, Yong Zhao, Yingfeng Zheng, Maigeng Zhou, Jun Zhu, Shankuan Zhu, Xiaonong Zou, Joseph R Zunt, Alan D Lopez, Theo Vos, Christopher J Murray
BACKGROUND: The Global Burden of Disease, Injuries, and Risk Factor study 2013 (GBD 2013) is the first of a series of annual updates of the GBD. Risk factor quantification, particularly of modifiable risk factors, can help to identify emerging threats to population health and opportunities for prevention. The GBD 2013 provides a timely opportunity to update the comparative risk assessment with new data for exposure, relative risks, and evidence on the appropriate counterfactual risk distribution...
December 5, 2015: Lancet
https://www.readbyqxmd.com/read/26195287/brain-structural-and-microstructural-alterations-associated-with-cerebral-palsy-and-motor-impairments-in-adolescents-born-extremely-preterm-and-or-extremely-low-birthweight
#12
Claire E Kelly, Linda Chan, Alice C Burnett, Katherine J Lee, Alan Connelly, Peter J Anderson, Lex W Doyle, Jeanie L Y Cheong, Deanne K Thompson
AIM: To elucidate neurobiological changes underlying motor impairments in adolescents born extremely preterm (gestation <28wks) and/or with extremely low birthweight (ELBW, <1000g), our aims were the following: (1) to compare corticospinal tract (CST) microstructure and primary motor cortex (M1) volume, area, and thickness between extremely preterm/ELBW adolescents and a comparison group with normal birthweight (>2499g); (2) to compare CST microstructure and M1 volume, area, and thickness between extremely preterm/ELBW adolescents with cerebral palsy (CP), motor impairment without CP, and no motor impairment; and (3) to investigate associations between CST microstructure and M1 measures...
December 2015: Developmental Medicine and Child Neurology
https://www.readbyqxmd.com/read/26158060/three-dimensional-brain-magnetic-resonance-imaging-segmentation-via-knowledge-driven-decision-theory
#13
Nishant Verma, Gautam S Muralidhar, Alan C Bovik, Matthew C Cowperthwaite, Mark G Burnett, Mia K Markey
Brain tissue segmentation on magnetic resonance (MR) imaging is a difficult task because of significant intensity overlap between the tissue classes. We present a new knowledge-driven decision theory (KDT) approach that incorporates prior information of the relative extents of intensity overlap between tissue class pairs for volumetric MR tissue segmentation. The proposed approach better handles intensity overlap between tissues without explicitly employing methods for removal of MR image corruptions (such as bias field)...
October 2014: Journal of Medical Imaging
https://www.readbyqxmd.com/read/25964253/simpson-s-paradox-and-the-impact-of-different-dnmt3a-mutations-on-outcome-in-younger-adults-with-acute-myeloid-leukemia
#14
Rosemary E Gale, Katarina Lamb, Christopher Allen, Dima El-Sharkawi, Cassandra Stowe, Sarah Jenkinson, Steven Tinsley, Glenda Dickson, Alan K Burnett, Robert K Hills, David C Linch
PURPOSE: To evaluate the impact of DNMT3A mutations on outcome in younger patients with cytogenetic intermediate-risk acute myeloid leukemia. PATIENTS AND METHODS: Diagnostic samples from 914 patients (97% < 60 years old) were screened for mutations in DNMT3A exons 13 to 23. Clinical outcome was evaluated according to presence or absence of a mutation and stratified according to type of mutation (R882, non-R882 missense, or truncation). RESULTS: DNMT3A mutations (DNMT3A(MUT)) were identified in 272 patients (30%) and associated with a poorer prognosis than wild-type DNMT3A, but the difference was only seen when the results were stratified according to NPM1 genotype...
June 20, 2015: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/25934048/impact-of-tobacco-usage-on-disease-outcome-in-myelodysplastic-syndromes
#15
Asmita Mishra, Dana E Rollison, Thomas H Brandon, Najla H Al Ali, Maria Corrales-Yepez, Eric Padron, Pearlie K Epling-Burnette, Jeffrey E Lancet, Alan F List, Rami S Komrokji
We hypothesized that tobacco usage is an independent prognostic factor in patients with myelodysplastic syndromes (MDS). To evaluate the impact of tobacco usage in this population, we identified patients diagnosed with MDS in our Center's MDS database and reviewed individual charts retrospectively. Of the 767 MDS patients identified, 743 patients (97%) had a known tobacco usage history. Given that the majority of tobacco users were smokers, we stratified patients as having never smoked (never-smoker group) versus current or former smokers (ever-smoker group)...
July 2015: Leukemia Research
https://www.readbyqxmd.com/read/25876768/an-immunophenotypic-pre-treatment-predictor-for-poor-response-to-induction-chemotherapy-in-older-acute-myeloid-leukaemia-patients-blood-frequency-of-cd34-cd38-low-blasts
#16
Naeem Khan, Sylvie D Freeman, Paul Virgo, Steve Couzens, Peter Richardson, Ian Thomas, Angela Grech, Paresh Vyas, David Grimwade, Nigel H Russell, Alan K Burnett, Robert K Hills
Many older patients with acute myeloid leukaemia (AML) that receive standard intensive chemotherapy fail to achieve complete remission (CR). Upfront identification of patients unlikely to benefit from standard induction chemotherapy would be important for exploration of novel therapies. This study evaluated if a flow cytometric assay measuring pre-treatment CD34(+) CD38(low) blast frequency could predict therapeutic-resistance in 736 AML patients entered into the UK National Cancer Research Institute AML16 trial...
July 2015: British Journal of Haematology
https://www.readbyqxmd.com/read/25833957/a-randomized-comparison-of-daunorubicin-90-mg-m2-vs-60-mg-m2-in-aml-induction-results-from-the-uk-ncri-aml17-trial-in-1206-patients
#17
RANDOMIZED CONTROLLED TRIAL
Alan K Burnett, Nigel H Russell, Robert K Hills, Jonathan Kell, Jamie Cavenagh, Lars Kjeldsen, Mary-Frances McMullin, Paul Cahalin, Mike Dennis, Lone Friis, Ian F Thomas, Don Milligan, Richard E Clark
Modifying induction therapy in acute myeloid leukemia (AML) may improve the remission rate and reduce the risk of relapse, thereby improving survival. Escalation of the daunorubicin dose to 90 mg/m(2) has shown benefit for some patient subgroups when compared with a dose of 45 mg/m(2), and has been recommended as a standard of care. However, 60 mg/m(2) is widely used and has never been directly compared with 90 mg/m(2). As part of the UK National Cancer Research Institute (NCRI) AML17 trial, 1206 adults with untreated AML or high-risk myelodysplastic syndrome, mostly younger than 60 years of age, were randomized to a first-induction course of chemotherapy, which delivered either 90 mg/m(2) or 60 mg/m(2) on days 1, 3, and 5 combined with cytosine arabinoside...
June 18, 2015: Blood
https://www.readbyqxmd.com/read/25805812/downregulation-of-the-wnt-inhibitor-cxxc5-predicts-a-better-prognosis-in-acute-myeloid-leukemia
#18
Andrea Kühnl, Peter J M Valk, Mathijs A Sanders, Adam Ivey, Robert K Hills, Ken I Mills, Rosemary E Gale, Martin F Kaiser, Richard Dillon, Melanie Joannides, Amanda Gilkes, Torsten Haferlach, Susanne Schnittger, Estelle Duprez, David C Linch, Ruud Delwel, Bob Löwenberg, Claudia D Baldus, Ellen Solomon, Alan K Burnett, David Grimwade
The gene CXXC5 on 5q31 is frequently deleted in acute myeloid leukemia (AML) with del(5q), suggesting that inactivation of CXXC5 might play a role in leukemogenesis. Here, we investigated the functional and prognostic implications of CXXC5 expression in AML. CXXC5 mRNA was downregulated in AML with MLL rearrangements, t(8;21) and GATA2 mutations. As a mechanism of CXXC5 inactivation, we found evidence for epigenetic silencing by promoter methylation. Patients with CXXC5 expression below the median level had a lower relapse rate (45% vs 59%; P = ...
May 7, 2015: Blood
https://www.readbyqxmd.com/read/25805811/vosaroxin-and-vosaroxin-plus-low-dose-ara-c-ldac-vs-low-dose-ara-c-alone-in-older-patients-with-acute-myeloid-leukemia
#19
RANDOMIZED CONTROLLED TRIAL
Mike Dennis, Nigel Russell, Robert K Hills, Claire Hemmaway, Nicki Panoskaltsis, Mary-Frances McMullin, Lars Kjeldsen, Helen Dignum, Ian F Thomas, Richard E Clark, Don Milligan, Alan K Burnett
The development of new treatments for older patients with acute myeloid leukemia is an active area, but has met with limited success. Vosaroxin, a quinolone-derived intercalating agent has several properties that could prove beneficial. Initial clinical studies showed it to be well-tolerated in older patients with relapsed/refractory disease. In vitro data suggested synergy with cytarabine (Ara-C). To evaluate vosaroxin, we performed 2 randomized comparisons within the "Pick a Winner" program. A total of 104 patients were randomized to vosaroxin vs low-dose Ara-C (LDAC) and 104 to vosaroxin + LDAC vs LDAC...
May 7, 2015: Blood
https://www.readbyqxmd.com/read/25413011/a-close-association-of-autoimmune-mediated-processes-and-autoimmune-disorders-with-chronic-myelomonocytic-leukemia-observation-from-a-single-institution
#20
COMPARATIVE STUDY
Deniz Peker, Eric Padron, John M Bennett, Xiaohui Zhang, Pedro Horna, Pearlie K Epling-Burnette, Jeffrey E Lancet, Javier Pinilla-Ibarz, Lynn Moscinski, Alan F List, Rami S Komrokji, Ling Zhang
Chronic myelomonocytic leukemia (CMML), a clonal hematopoietic stem cell disease, may be linked to immune-mediated processes and/or autoimmune disorders (AID), although the exact pathogens are still elusive. We retrospectively analyzed 123 CMML patients in our institution. Twenty-four CMML patients (19.5%) had at least one immune-mediated disorder, most commonly idiopathic thrombocytopenic purpura, gout and psoriasis. Four of these 24 patients (15%) had more than one AID. We found that, in contrast to the general population with a prevalence rate of 3...
2015: Acta Haematologica
keyword
keyword
112213
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"